Systematic Therapy for Unresectable or Metastatic Soft-Tissue Sarcomas: Past, Present, and Future
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Sherif S. Morgan & Lee D. Cranmer
- چاپ و سال / کشور: 2011
Description
Unresectable or metastatic disease occurs in 40% to 60% of soft-tissue sarcoma (STS) patients and portends a poor prognosis. For decades, doxorubicin has formed the backbone of systemic treatment, with response rates of approximately 26%. Patients progressing following firstline therapy were left with few proven options. No other cytotoxic chemotherapy agent or combination has demonstrated superiority to doxorubicin. Advances in targeted therapy of STS have been hindered by STS heterogeneity and poorly understood disease biology. Despite challenges, progress has been made in specific STS subtypes. Here, we highlight the challenges, progress, and lessons learned from STS trials published in the last 20 to 25 yea
Curr Oncol Rep (2011) 13:331–349 DOI 10.1007/s11912-011-0182-z Published online: 2 June 2011
